2.67
price down icon2.91%   -0.08
after-market アフターアワーズ: 2.69 0.02 +0.75%
loading
前日終値:
$2.75
開ける:
$2.8
24時間の取引高:
11,279
Relative Volume:
0.30
時価総額:
$46.21M
収益:
$709.00K
当期純損益:
$-43.14M
株価収益率:
-0.26
EPS:
-10.27
ネットキャッシュフロー:
$-20.35M
1週間 パフォーマンス:
-4.64%
1か月 パフォーマンス:
-14.42%
6か月 パフォーマンス:
-5.32%
1年 パフォーマンス:
-33.08%
1日の値動き範囲:
Value
$2.56
$2.80
1週間の範囲:
Value
$2.50
$2.80
52週間の値動き範囲:
Value
$2.285
$4.305

OncoCyte Corporation Stock (OCX) Company Profile

Name
名前
OncoCyte Corporation
Name
セクター
Healthcare (1196)
Name
電話
510-775-0515
Name
住所
1010 Atlantic Avenue, Suite 102, Alameda, CA
Name
職員
16
Name
Twitter
@OncocyteCorp
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
OCX's Discussions on Twitter

OCX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
OCX 2.67 46.21M 709.00K -43.14M -20.35M -10.27
VRTX 450.37 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 24.89B 3.30B -501.07M 1.03B 11.54

OncoCyte Corporation Stock (OCX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2022-05-24 ダウングレード Stephens Overweight → Equal-Weight
2022-03-14 ダウングレード KeyBanc Capital Markets Overweight → Sector Weight
2022-01-07 開始されました Stephens Overweight
2022-01-06 再開されました Piper Sandler Overweight
2021-03-17 再開されました Needham Buy
2021-01-07 アップグレード The Benchmark Company Speculative Buy → Buy
2020-12-16 アップグレード Piper Sandler Neutral → Overweight
2020-11-30 開始されました BTIG Research Buy
2020-11-10 開始されました KeyBanc Capital Markets Overweight
2020-07-30 繰り返されました The Benchmark Company Speculative Buy
2020-07-01 ダウングレード Piper Sandler Overweight → Neutral
2020-06-30 ダウングレード Chardan Capital Markets Buy → Neutral
2020-06-02 開始されました Needham Buy
2019-02-13 開始されました Piper Jaffray Overweight
2019-01-29 アップグレード Janney Neutral → Buy
2018-12-19 再開されました Lake Street Buy
すべてを表示

OncoCyte Corporation (OCX) 最新ニュース

pulisher
Nov 15, 2024

Seasoned Financial executive joins Oncocyte as CFO - Reuters.com

Nov 15, 2024
pulisher
Nov 14, 2024

PURA VIDA INVESTMENTS, LLC Expands Stake in OncoCyte Corp - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

OncoCyte stock maintains Buy rating with Needham after GraftAssure RUO launch - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

OncoCyte Corporation (NASDAQ:OCX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

OncoCyte: Q3 Earnings Snapshot - Darien Times

Nov 13, 2024
pulisher
Nov 13, 2024

OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress i - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ... - Yahoo Finance

Nov 13, 2024
pulisher
Nov 12, 2024

OncoCyte Corp Reports Q3 2024 Earnings and Strategic Updates - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

OncoCyte Corp (OCX) Q3 2024 Earnings: EPS of -$0.98 Misses Estimates, Revenue Falls Short at $115,000 - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

Oncocyte Corporation (OCX) Quarterly 10-Q Report - Quartz

Nov 12, 2024
pulisher
Nov 11, 2024

What to Expect from OncoCyte's Earnings - Benzinga

Nov 11, 2024
pulisher
Nov 06, 2024

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 - ForexTV.com

Nov 06, 2024
pulisher
Nov 02, 2024

OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - MarketBeat

Nov 02, 2024
pulisher
Oct 27, 2024

StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX) - MarketBeat

Oct 27, 2024
pulisher
Oct 17, 2024

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles - The Manila Times

Oct 17, 2024
pulisher
Oct 16, 2024

Oncocyte Corp expands equity incentive plan - Investing.com India

Oct 16, 2024
pulisher
Oct 16, 2024

Oncocyte Corp expands equity incentive plan By Investing.com - Investing.com Australia

Oct 16, 2024
pulisher
Oct 16, 2024

OncoCyte shares maintain Buy rating from Needham By Investing.com - Investing.com Nigeria

Oct 16, 2024
pulisher
Oct 15, 2024

OncoCyte shares maintain Buy rating from Needham - Investing.com

Oct 15, 2024
pulisher
Oct 09, 2024

OncoCyte Corp (OCX) Q2 2024 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - Yahoo Finance

Oct 09, 2024
pulisher
Oct 08, 2024

Oncocyte reports breakthrough in breast cancer diagnostics - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial - The Manila Times

Oct 08, 2024
pulisher
Oct 08, 2024

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial - StockTitan

Oct 08, 2024
pulisher
Oct 05, 2024

Broadwood Partners L.P. buys Oncocyte shares for $3.88 million By Investing.com - Investing.com Australia

Oct 05, 2024
pulisher
Oct 04, 2024

Oncocyte CFO acquires $99,999 worth of company shares By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 04, 2024

Oncocyte CFO acquires $99,999 worth of company shares - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

Broadwood Partners L.P. buys Oncocyte shares for $3.88 million - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

OncoCyte Secures Funding Through Private Share Sale - Yahoo Finance

Oct 04, 2024
pulisher
Oct 03, 2024

OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc. - Marketscreener.com

Oct 03, 2024
pulisher
Oct 03, 2024

LENSAR reports inducement grants - Medical Buyer

Oct 03, 2024
pulisher
Oct 03, 2024

Oncocyte Corporation enters into securities purchase agreement - Medical Buyer

Oct 03, 2024
pulisher
Oct 03, 2024

Oncocyte Signs Leading Transplant Centers in US and Germany - The Manila Times

Oct 03, 2024
pulisher
Oct 02, 2024

Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules - ForexTV.com

Oct 02, 2024
pulisher
Oct 02, 2024

Sandfire Resources America Inc. Announces Incentive Plan Grants - The Manila Times

Oct 02, 2024

OncoCyte Corporation (OCX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.56%
$367.36
price up icon 0.77%
$194.56
price up icon 0.07%
$108.23
price up icon 5.98%
大文字化:     |  ボリューム (24 時間):